CureVac AG

CureVac AG

CureVac uses mRNA as an information carrier, which enables the body to produce its own active ingredients for the fight against various diseases.

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 900 people across its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.

Category Biotechnology
Working areas Biotechnology, Research, Medical products, Production
Year of foundation
2000
Employees
900

News

16.11.2022

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced…

05.07.2022

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

ureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that…

08.06.2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

  Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight…

08.06.2022

CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen

  Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.…